How many clinical trials are studying Alemtuzumab?

10 recruiting trials in our tracked data involve Alemtuzumab.

What conditions is Alemtuzumab being studied for?

In our tracked recruiting trials, Alemtuzumab is being studied in trials for Sickle Cell Disease, Crohn's Disease, Beta-thalassemia.

Alemtuzumab: clinical trials recruiting now

Q: Is Alemtuzumab FDA-approved?

Yes. According to the FDA drug label available through openFDA, Alemtuzumab is an FDA-approved drug. Its FDA label carries a boxed warning.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Alemtuzumab appears in the FDA drug-label database. Marketed as Campath.
Drug class: CD52-directed Cytolytic Antibody (FDA established pharmacologic class)
Mechanism of action: CD52-directed Antibody Interactions (as stated on the FDA label)
Boxed warning: The FDA label for Alemtuzumab carries a boxed warning (the FDA's most serious warning). See the full label for details.

FDA-approved use

CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). CAMPATH is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). ( 1 )

FDA label via openFDA

Phase breakdown

Phase 1 4 Phase 2 10

Conditions being studied

Condition	Trials
Sickle Cell Disease · Alemtuzumab for Sickle Cell Disease	7
Crohn's Disease	2
Beta-thalassemia	1
Beta-thalassemia Major	1
COPD	1
Congenital Bone Marrow Failure Syndromes	1
Diamond-blackfan Anemia	1
Diffuse Sclerosis Systemic	1
Emphysema or COPD	1
Graft Failure	1
Hemoglobinopathies	1
Hereditary Anemias	1
Hypertension	1
Idiopathic Pulmonary Fibrosis	1
Inflammatory Conditions	1

Recruiting trials involving Alemtuzumab

Allo HSCT for High Risk Hemoglobinopathies
NCT06872333 · Phase: Phase 2 · Ages: Up to 55 Years · Sex: All (male and female) · 1 location
Autologous Stem Cell Transplantation for Crohn's Disease
NCT00692939 · Phase: Phase 1, Phase 2 · Ages: 10 Years to 60 Years · Sex: All (male and female) · 2 locations
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
NCT03630211 · Phase: Phase 2 · Ages: 8 Years to 60 Years · Sex: All (male and female) · 3 locations
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
NCT07616154 · Phase: Phase 2 · Ages: Up to 22 Years · Sex: All (male and female) · 1 location
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
NCT03500731 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 2 locations
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
NCT03214354 · Phase: Phase 2 · Ages: 1 Year to 19 Years · Sex: All (male and female) · 1 location
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
NCT07599176 · Phase: Phase 1, Phase 2 · Ages: 4 Years to 65 Years · Sex: All (male and female) · 1 location
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
NCT01962415 · Phase: Phase 2 · Ages: 2 Months to 55 Years · Sex: All (male and female) · 2 locations
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
NCT06358638 · Phase: Phase 2 · Ages: 2 Years to 25 Years · Sex: All (male and female) · 1 location
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
NCT03653338 · Phase: Phase 1, Phase 2 · Ages: 5 Years to 40 Years · Sex: All (male and female) · 1 location

Common questions

Is Alemtuzumab FDA-approved?

Yes, marketed as Campath. Its FDA label carries a boxed warning.

How many recruiting trials involve Alemtuzumab?

10 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.